Copenhagen, Denmark, November 12, 2018 – RetiPharma, focusing on the development of products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to humans, is pleased to announce that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII). The funding will be Read more RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disorders